Aduro BioTech Inc (NASDAQ:ADRO) rose 12.1% during trading on Thursday . The company traded as high as $2.89 and last traded at $2.88. Approximately 1,011,701 shares traded hands during mid-day trading, an increase of 93% from the average daily volume of 522,997 shares. The stock had previously closed at $2.57.

ADRO has been the topic of a number of analyst reports. HC Wainwright set a $8.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Monday, November 12th. Zacks Investment Research lowered shares of Aduro BioTech from a “buy” rating to a “hold” rating in a research note on Thursday. BidaskClub raised shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Friday, August 31st. Oppenheimer set a $10.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Tuesday, October 30th. Finally, Cowen reaffirmed a “buy” rating on shares of Aduro BioTech in a research note on Wednesday, October 31st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.63.

The company has a market cap of $228.68 million, a P/E ratio of -1.89 and a beta of 2.57.

Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings data on Tuesday, October 30th. The biotechnology company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.02. Aduro BioTech had a negative net margin of 591.66% and a negative return on equity of 50.03%. The company had revenue of $3.06 million for the quarter, compared to analyst estimates of $4.59 million. As a group, equities research analysts forecast that Aduro BioTech Inc will post -1.18 EPS for the current fiscal year.

In related news, CFO Jennifer Lew sold 5,623 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.50, for a total transaction of $36,549.50. Following the transaction, the chief financial officer now owns 141,813 shares in the company, valued at approximately $921,784.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stephen T. Isaacs sold 24,143 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.50, for a total transaction of $156,929.50. Following the transaction, the insider now owns 356,996 shares in the company, valued at approximately $2,320,474. The disclosure for this sale can be found here. Insiders have sold a total of 46,927 shares of company stock worth $294,918 in the last quarter. 5.00% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Aduro BioTech by 9.9% during the third quarter. Vanguard Group Inc. now owns 4,029,445 shares of the biotechnology company’s stock worth $29,617,000 after acquiring an additional 362,516 shares in the last quarter. MetLife Investment Advisors LLC raised its stake in shares of Aduro BioTech by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 49,337 shares of the biotechnology company’s stock worth $363,000 after acquiring an additional 17,538 shares in the last quarter. Aquilo Capital Management LLC raised its stake in shares of Aduro BioTech by 4.8% during the third quarter. Aquilo Capital Management LLC now owns 2,105,282 shares of the biotechnology company’s stock worth $15,474,000 after acquiring an additional 97,383 shares in the last quarter. Jefferies Group LLC raised its stake in shares of Aduro BioTech by 263.5% during the third quarter. Jefferies Group LLC now owns 46,532 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 33,732 shares in the last quarter. Finally, Baillie Gifford & Co. raised its stake in shares of Aduro BioTech by 9.5% during the third quarter. Baillie Gifford & Co. now owns 3,076,825 shares of the biotechnology company’s stock worth $22,615,000 after acquiring an additional 266,317 shares in the last quarter. Institutional investors own 48.32% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/aduro-biotech-adro-stock-price-up-12-1/2671272.html.

About Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Featured Article: How is Preferred Stock Different from Common Stock?

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.